TD Cowen raised the firm’s price target on Cardinal Health (CAH) to $150 from $144 and keeps a Buy rating on the shares. The firm said they continue to see upside to numbers despite the company raising its FY25 adj. EPS and Pharma guides, which largely reflects F2Qs Pharma beat and M&A contribution and does not carry forward strong drug utilization seen in F1H.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $154 from $149 at Baird
- Cardinal Health Reports Earnings and Raises Outlook
- Cardinal Health price target raised to $156 from $138 at Leerink
- Morning Movers: UPS and Cigna plunge double digits following Q4 results
- Cardinal Health Reports Mixed Q2 Results Amid Strategic Growth